Summary
This study is testing a medicine called TLN-372 when taken together with cobicistat.
The study aims to:
- find out whether TLN-372 is safe when taken with cobicistat
- understand how the body absorbs, processes, and removes TLN-372 when it is given with cobicistat
- learn wheather TLN-372 may help treat cancers with a KRAS gene mutation that have spread or cannot be removed with surgery
Who can take part?
You may be able to join this study if you:
- are aged 18 years or old
- have a locally advanced or metastatic solid tumour
- your cancer has a KRAS mutation
- are well enough to carry out normal daily activities (ECOG performance status 0 or 1)
- have adequate organ function
What does participation involve?
If you join this study, you will receive TLN-372 and cobicistat.
During the study, you will be monitored with regular clinic visits, blood tests and medical imaging scans.
Researchers hope this study will show whether TLN-372 can be safely used with cobicistat and whether this combination may help treat cancers with a KRAS mutation. The results may help support the future development of new treatment options for people with KRAS-mutant cancers.